Blog | BioInformant

Aspen Neuroscience Advances Sasineprocel, an Autologous iPSC-Based Therapy for Parkinson’s Disease, Toward Phase 3

September 25, 2026 By BioInformant Team Leave a Comment

Aspen Neuroscience Announces Publication of Sasineprocel Preclinical Data in “Cell Stem Cell”

Peer-reviewed findings describe reproducible manufacturing, leading-edge genomic quality controls and preclinical evidence supporting clinical development of an autologous iPSC-derived neuron replacement therapy for Parkinson’s disease, now entering Phase 3

SAN DIEGO, Sept. 18, 2026 — Aspen Neuroscience, Inc., a clinical-stage regenerative medicine biotechnology company developing personalized, autologous cell therapies for Parkinson’s disease (PD), today announced publication of “Autologous iPSC-Derived Cell Therapy for Parkinson’s Disease: Preclinical Evaluation through Genomic Quality Controls” in Cell Stem Cell. [Read more…]

A Complete List of All Publicly Announced RMAT Designations (173)

September 23, 2026 By Cade Hildreth, Founder & President 8 Comments

To date, what number of U.S. FDA-approved RMATs have been issued and to whom have they been awarded?

The answer is that 173 RMAT (Regenerative Medicine Advanced Therapy) designations have been publicly announced by biotech and pharma companies. However, the FDA states it has received 388 requests and issued 193, which means that a handful are not yet public knowledge. Therefore, a few companies are operating in stealth mode with regard to their RMAT designations and approximately half of RMAT applications get approved (193 approvals / 388 applications = 49.7%).

[Read more…]

The Little Known History of MSCs (Year-By-Year)

September 23, 2026 By Cade Hildreth, Founder & President 1 Comment

Mesenchymal stem cells (MSCs) are multipotent stem cells that can differentiate into a variety of cell types, including osteoblasts, chondrocytes, myocytes, and adipocytes. MSCs are of intense therapeutic interest, because they represent a population of cells with the potential to treat a range of acute and degenerative diseases. MSCs are advantageous over other stem cells types for a variety of reasons, including that they are immunoprivileged, making them an advantageous cell type for allogeneic transplantation.

Allogeneic means that cells from a donor are used in the treatment of a different person.

Overview of Mesenchymal Stem Cells (MSCs)

In addition to secreting factors that can stimulate tissue repair, MSCs can substantially alter their microenvironment, exerting effects that are both anti-inflammatory and anti-fibrotic. MSCs are also advantageous over other stem cells types, because they avoid the ethical issues that surround embryonic stem cell research and can positively impact immune function. Because of their unique capacity to form structural tissues, MSCs also being explored for use in 3D printing applications.

History of Mesenchymal Stem Cells (MSCs)

1900s

The discovery of mesenchymal stem cells (MSCs) dates back to the early 1900’s.

1924

In 1924, the Russian-born researcher Alexander Maximow used histology to identify a type of precursor cell within the mesenchyme that could differentiate into a variety of blood cell types.[1] While the term mesenchymal stem cell did not exist, this is the earliest known reference to the cell type.

1960s

Nearly 40 years later, in the 1960’s, researchers Ernest McCulloch and James Till identified the clonal qualities of marrow cells. [2],[3] It then took another decade until an ex vivo assay was developed that allowed for examination of the clonal nature of multipotent marrow cells.[4] [Read more…]

MUSE Cells Now Available at Longevity Medical Institute®

September 19, 2026 By BioInformant Team Leave a Comment

As part of its Regenerative Neurology Program, Longevity Medical Institute® is making MUSE cell therapy available to select patients, using cells produced in-house at the Institute’s biotechnology laboratory.

SAN JOSÉ DEL CABO, BAJA CALIFORNIA SUR, MEXICO, September 18, 2026 – Longevity Medical Institute® today announced the addition of MUSE cells to the advanced cell types produced in its in-house biotechnology laboratory.

“By isolating, enriching, and characterizing the MUSE cell population within the MSC cultures already produced in our in-house biotechnology laboratory, we have greater control over quality evaluation, release, and delivery for patient care,” said Dr. Kirk Sanford, founder and CEO of Longevity Medical Institute.

Longevity Medical Institute’s exclusive biotechnology partner, ITC, developed the MUSE stem cell product. MUSE stands for multilineage-differentiating stress-enduring. The recognized starting phenotype includes SSEA-3 and CD105 double positivity, supported by OCT3/4, SOX2, and NANOG. S1PR2 is associated with their proposed injury-directed migration. [Read more…]

Exosomes: Company Spotlights from “A” to “Z”

September 17, 2026 By Cade Hildreth, Founder & President 10 Comments

Exosomes are small vesicles ranging from 30-100nm in size that are found in nearly all eukaryotic fluids and facilitate a range of important cellular functions. They transfer DNA, RNA, and proteins to other cells, thereby altering the function of the targeted cells. In recent years, exosomes have gained attention as a strategy for accessing the therapeutic effects of cells without the risks and difficulties of administering the cells to patients.

With at least 26,805 scientific articles published about exosomes and 301 clinical trials underway, these small vesicles have intriguing potential to be used within a range of therapeutic applications. The term “exosomes” has become an increasingly common Search Term on Google over the past 10 years, as shown in the graph below: [Read more…]